A Study to Evaluate Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata
The purpose of this study is to evaluate the efficacy of baricitinib.
- Subject must self-identify as Black or African American
- Subject's current episode of alopecia areata must be more than 6 months and no longer than 8 years
- Subject must not have any spontaneous improvement
- Subject must be in good general health with no history of tuberculosis, heart disease, cancer, HIV, hepatitis B or C, or blood clots
- Female subjects must not be pregnant, breastfeeding, or considering becoming pregnant for the duration of the study
A Study to Evaluate Rocatinlimab in Adults with Atopic Dermatitis (Ezcema)
Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
The purpose of this study is to evaluate the efficacy of rocatinlimab.
- Subject must have a diagnosis of atopic dermatitis for a least 6 months prior to study visit
- Subject must have tried a topical medication with little to no improvement
- Subject must be in good general health with no history of tuberculosis, heart disease, cancer, HIV, hepatitis B or C, or blood clots
- Female subjects must not be pregnant, breastfeeding, or considering becoming pregnant for the duration of the study
A Study to Evaluate Povorcitinib in Adults with Hidradenitis Suppurativa (HS)
The purpose of this study is to evaluate the efficacy of povorcitinib.
- Subject must have a diagnosis of hidradenitis suppurativa for at least 3 months prior to study visit
- Subject must have at least 5 active HS spots in 2 different body areas
- Subject must have tried an oral or injected medication for HS with little to no improvement
- Subject must be in good general health with no history of tuberculosis, heart disease, cancer, HIV, hepatitis B or C, or blood clots
- Female subjects must not be pregnant, breastfeeding, or considering becoming pregnant for the duration of the study
A Study to Evaluate Upadacitinib Along with Topical Corticosteroids on Teens and Adults with Atopic Dermatitis (eczema)
The purpose of this study is to compare the effectiveness and safety of Upadacitinib (ABT-494) to placebo (pill without any active substance that looks like upadacitinib) in combination with topical corticosteroids for adolescents (12-17 years of age) and adults (18-75 years of age with moderate to severe atopic dermatitis (AD).
- Adolescent subjects must weigh more than 40 kg (88 lb) - Subject must be in good general health (other than Atopic Dermatitis) - Subject must have chronic Atopic Dermatitis (AD) with onset of symptoms at least 3 years before first dose of study medication - Subject must have documented history of inadequate response to topical corticosteroids (TCS), topical calcineurin inhibitor (TCI), or systemic treatment for AD within 6 months prior to first dose of study medication - Female subjects must not be pregnant, breastfeeding, or considering becoming pregnant for the duration of the study and for 30 days after last dose of the study drug. - No history of drug or alcohol abuse in the 6 months prior to receiving the first dose of study medication